



AmerisourceBergen

2021 Summary Annual Report



| | |
|----|------------------------------------|
| 04 | About AmerisourceBergen |
| 07 | CEO statement |
| 20 | Financial highlights |
| 22 | Management team |
| 23 | Board of Directors |
| 24 | GAAP / Non-GAAP financial measures |
| 26 | Corporate information |

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over \$200 billion in annual revenue, AmerisourceBergen is headquartered in Conshohocken, PA, and employs approximately 42,000 people around the world. AmerisourceBergen is ranked #8 on the Fortune 500 list.

We distribute a comprehensive offering of brand name and generic pharmaceuticals – including specialty pharmaceutical products, over-the-counter healthcare products, home healthcare supplies and equipment and related services to a wide variety of healthcare providers located in the United States, Europe, and select global markets. Our customers include chain retail and independent pharmacies, mail order pharmacies, acute care hospitals and health systems, physician practices, medical and dialysis clinics, long-term care and other alternate site pharmacies, veterinarians, and others. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related high-value services, including reimbursement and pharmaceutical consulting services, niche premium logistics services, inventory management, pharmacy automation, and pharmacy management.

Please visit our website, investor.amerisourcebergen.com for the most current corporate news and financial results.





To our Shareholders

In fiscal 2021, AmerisourceBergen advanced its role as a key pillar of pharmaceutical innovation and access as we lived our purpose of being united in our responsibility to create healthier futures by supporting our partners, customers, and team members through challenging times.

As the pandemic persists, the importance of our purpose and role in an evolving healthcare environment has never been more important. We are proud to be able to offer our expertise, capabilities, and infrastructure as part of the solution, from facilitating the national distribution of COVID-19 therapies to supporting the distribution of tens of millions of vaccines to patients in over 30 countries through our expanded global footprint.

We have leveraged the strength of our business and expertise to become an increasingly vital partner through differentiated solutions for our upstream and downstream customers of all sizes. Our continuous investments have deepened our relationships with all our stakeholders during this time of increased focus on the pharmaceutical supply chain.

We remain purpose-driven and well positioned to create significant stakeholder value. The AmerisourceBergen team made exceptional progress on our strategic priorities during fiscal 2021, and we will capitalize on that momentum to continue executing and innovating in fiscal 2022.



Creating differentiated value for all our stakeholders

Driven by our resilience and strength, high level of execution, and exceptional performance across our businesses in fiscal 2021, we grew revenue by 13% to \$214 billion and adjusted diluted earnings per share by 17% to \$9.26. In addition to strong fundamentals across our business, our results were enhanced by the addition of Alliance Healthcare, growth in our higher margin businesses, and the important work our team has done to support COVID-19 therapy distribution.

Our Pharmaceutical Distribution Services segment delivered revenue growth of 9%. This segment continued to benefit from our industry-leading customer relationships, our leadership in specialty distribution and commercialization services, and strong end-market trends. Through our long-term relationships, such as our extended and expanded partnership with Walgreens, we are able to provide value-added solutions that further strengthen our ability to lead with market leaders. Our robust suite of specialty distribution capabilities and our deep industry expertise uniquely position us to support our partners; in the U.S., we continue to be a leading distributor of COVID-19 therapies, and internationally, we are playing a role in the distribution of COVID-19 vaccines.

As pharmaceutical trends continue to evolve, we are proud to leverage our unique capabilities and expertise to support our customers, partners, and the healthcare system overall. From responding to public health challenges to supporting the growth of biosimilars and new pharmaceutical innovations, AmerisourceBergen remains well positioned to facilitate patient access, wherever a prescription is needed.

Our Alliance Healthcare, Global Commercialization Services and Animal Health businesses delivered strong results in 2021, growing revenue 112% due to strong execution and the June 2021 acquisition of Alliance Healthcare. As global logistics continued to be challenged by the pandemic, World Courier provided its expertise and innovative solutions to manufacturer partners around the world, facilitating the movement of temperature-sensitive and other high-priority shipments. World Courier's direct-to-patient, in-home clinical trials remained a differentiator as patients and manufacturers sought alternative, lower acuity care sites. Our MWI Animal Health business also

Fiscal 2021 revenue increased

13% to \$214 billion

Adjusted diluted earnings per share increased

17% to \$9.26¹

¹ See Appendix A for more information regarding the non-GAAP financial measure adjusted diluted earnings per share.

experienced strong performance in the companion animal market as pet owners maintained their focus on their pets' health. In the production animal market, the global need for protein continues.

Alliance Healthcare has continued to deliver solid performance and meaningfully contributed to our results in the last four months of fiscal 2021 since the early close of the acquisition. Our culturally aligned teams have been working diligently to integrate our operations, conducting deep dives to realize operational and business development synergies and to explore ways to enhance the value we create for our customers and partners. We are excited by the opportunities created from this next evolution of enhancing our ability to provide innovative and global healthcare solutions.

Leadership in global healthcare solutions

As a leader in pharmaceutical distribution, differentiated by value-added solutions and complementary higher-margin businesses, AmerisourceBergen has built a clear leadership position as a provider of global healthcare solutions.

We offer a robust portfolio of unique solutions to our upstream partners, including facilitating direct-to-patient clinical trials, offering practical applications of innovative data and analytics capabilities, and helping manufacturers around the world navigate the ever-increasing complexities of global logistics. We also leverage our now expanded portfolio of international relationships, partnerships, and innovations to facilitate patient access to the rapidly evolving landscape of new pharmaceutical technologies.

Downstream, we remain a key partner for community pharmacies, veterinarians, physician practices, health systems, and more. In community pharmacy, we are particularly proud to support our Good Neighbor Pharmacy members' trusted role through our innovative tools and programs that allow independent pharmacists to optimize their operations and maximize the time they spend serving their patients and communities. This year, for the fifth year in a row—and for the tenth year of the past twelve years—Good Neighbor Pharmacy Network was ranked highest among brick-and-mortar chain drug store pharmacies by J.D. Power.

In our animal health business, we support veterinarian practices in similar ways to help them manage their practices as they continue to experience increased demand for their services due to growth in pet ownership, the cherished role of pets within families, and the increased importance placed upon ensuring health and well-being for all family members.

Our leading portfolio of key anchor customers now includes an expanded and extended relationship with Walgreens, a long-term relationship with Boots in the U.K., and a network of thousands of independent pharmacies

As we continue to drive our business forward, we will maintain our focus on our differentiated and strong customer base, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship.



across Europe through the Alphega Pharmacy network. Through our strategic partnership model, we form long-lasting relationships with key customers that integrate us into their day-to-day operations, enable us to provide value-added solutions, and further strengthen our ability to lead with market leaders.

Our ability to support pharmaceutical innovation through a global footprint with broad leadership and local expertise enables us to become the “partner of choice” to both upstream partners and downstream customers through our global and innovative services platform, providing a differentiated value proposition for our all our stakeholders.

Expanding on our leadership in specialty

Even as we focus on our global and innovative services platform, AmerisourceBergen continues to differentiate ourselves as the leader in specialty distribution in the United States. This year, we launched a variety of new services and solutions, building upon our historic investments to further expand our leadership in specialty and provide enhanced value to our customers and partners. For example, through our ION GPO and other value-added solutions, we formed new partnerships that offer industry-leading technologies to Specialty Physician Services’ customer practices, enabling them to be even more efficient while improving the patient experience and ultimately, outcomes.

Our continued investment in – and focus on – an important part of the pharmaceutical market continues to benefit both AmerisourceBergen and our partners. Our sourcing and commercial teams’ ability to leverage our expertise and data and analytics capabilities have been foundational to our ability to play an important role in providing the specialty distribution solutions for COVID-related treatments. We deliver a clear and differentiated value proposition for our partners in the U.S. healthcare system and continue to focus on building on our strengths in specialty distribution as these capabilities become even more important to all our stakeholders.

Execution excellence and investing in our business

As we continue to differentiate our business, we remain focused on being strategic partners to our customers as we help them achieve operational efficiencies and support growth in their businesses through innovative solutions. This means that we embrace advanced technologies, data, and analytics to further support positive outcomes through our global platform.

In fiscal 2021, AmerisourceBergen received the Industry Leader award at the 2021 SAP Innovation Awards for our work in developing SAP Advanced Track and Trace for Pharmaceuticals. This technology tracks millions of daily shipments at the batch level and further strengthens the pharmaceutical supply chain in the U.S. As a global healthcare company, we understand and appreciate the importance of ensuring our businesses have the technology they need to enable their operations, enhance their capabilities, and support a resilient and sustainable global pharmaceutical supply chain.





Addressing the opioid epidemic

In July 2021, the distribution industry reached a milestone regarding the proposed settlement agreement to address opioid-related claims of U.S. state attorneys general and political subdivisions in participating states. Throughout the litigation process, AmerisourceBergen has been consistent in stating our desire to address the enormity of the opioid challenge by bringing solutions to the table. If the industry's proposed agreement and settlement process leads to a final settlement, it would collectively provide thousands of communities across the United States with substantial financial support.

We take our role in the pharmaceutical supply chain seriously and continue to work closely with stakeholders concerning these complex matters. We will continue to work diligently and alongside partners to combat drug diversion while supporting real solutions to help address the crisis in the communities where we live, work, and serve.

Focus on corporate stewardship and long-term, sustainable growth

AmerisourceBergen has a history of successful corporate stewardship that focuses on financial health, our people and culture, and long-term, sustainable value creation.

In fiscal 2021, we returned \$449 million to our shareholders through opportunistic share repurchases and dividends, and invested \$438 million in our businesses through capital expenditures.

We continue to take a thoughtful and strategic approach to capital deployment that focuses on value creation and maintaining financial strength. This includes a focus on maintaining our strong investment-grade credit ratings, and we remain on track to deliver on our commitments to the rating agencies. Notably, our financial and strategic position has allowed us to continue to invest in expanding our capabilities, including through the highly accretive acquisition of Alliance Healthcare. In addition to the positive contribution to our financial results, our new team members are talented and purpose-driven, and I thank the combined AmerisourceBergen and Alliance Healthcare teams for their ongoing support of our integration efforts.

Our financial strength also enables us to continue to invest in our people and culture. At AmerisourceBergen, we know our team members are our most valuable asset, and we are committed to inspiring them to achieve their fullest potential. Our efforts go well beyond simply offering market-aligned pay, and we understand the long-term advantage of being a fair and

equitable employer who offers competitive wages at all levels. We have surveyed our team members to find out what is most valuable to them and have invested in attractive benefit programs such as increased paid parental leave, child and dependent care, and enhanced mental health and wellness programs. Our team members also value a culture of flexibility, and we have responded with a thoughtfully designed new way of working that provides options for flexibility while balancing the need for in-person connection and innovation.

From ensuring the safety of themselves and their loved ones during the pandemic to investing in world-class learning technology and models, we understand it is critical that our talent is cultivated and empowered to help drive our long-term growth. Our efforts continue to be recognized, with AmerisourceBergen once again named a Great Place to Work company and a Best Place to Work for LGBTQ Equality by the Human Rights Campaign.

Meaningful value can also be unlocked when individuals are empowered to bring their whole selves to work, and we embrace our collective differences. This year, we furthered our diversity, equity, and inclusion efforts with the rollout of new employee resource groups and new diverse candidate slate objectives. To further align our people strategy with our business strategy, we also introduced a new leadership competency model that will be embedded throughout all of our talent programs. Based on the collective feedback from team members across AmerisourceBergen, the new model focuses on developing leadership competencies aligned to four key business and cultural goals: diversity, equity, and inclusion; collaboration; innovation and executional excellence; and purpose. As the foundation for how we will recruit, engage, and develop our people, this new model and the principles behind it will enable us to create value now and for the long term.

Another aspect of our culture that helps ensure sustainable value creation is our dedication to operating in a sustainable and responsible manner, and to supporting healthy and resilient communities where we live and work. This year, we are proud to have published our fifth annual Global Sustainability & Corporate Responsibility Report, which aligns with the leading global sustainability frameworks. We also became a member of the SASB Standards Advisory Group, joined the Science Based Targets Initiative, and became a participant of the UN Global Compact, the world's largest corporate sustainability initiative.

Our continued progress in areas like ESG; diversity, equity, and inclusion; and strategic planning are made possible by the expert oversight and guidance of our Board, as well as the ability of our management team to drive execution and operational excellence.



Looking ahead

AmerisourceBergen has made exceptional progress this year on our strategic priorities, further enhancing our differentiated value proposition and driving consistent outperformance. As we continue to capitalize on our positive momentum into fiscal 2022, we remain driven by our purpose. Now powered by 42,000 team members globally, we remain confident in our pharmaceutical-centric strategy and capabilities as a leader in pharmaceutical distribution services and differentiated manufacturer solutions.

As we continue to drive our business forward, we will maintain our focus on our differentiated and strong customer base, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship. We are built on a foundation of leadership in pharmaceutical distribution differentiated by complementary higher margin businesses that leverage our pharmaceutical scale and expertise to create unparalleled value for our manufacturer partners and healthcare provider customers.

AmerisourceBergen is well-positioned to continue to create long-term shareholder value and to deliver on our purpose of being united in our responsibility to create healthier futures.

Thank you for your support and investment in AmerisourceBergen.

Sincerely,

A handwritten signature in black ink, reading "Steven H. Collis". The signature is fluid and cursive, with the first name "Steven" and last name "Collis" clearly distinguishable.

Steven H. Collis
Chairman, President & Chief Executive Officer




Financial highlights

FY21 Revenue




FY21 Adjusted Operating Income³



Balanced Capital Deployment⁴

Trailing 5 fiscal years



¹ Includes \$139M of intersegment eliminations and primarily represents the elimination of certain Pharmaceutical Distribution Services reportable segment sales to MWI.

² Reported as Other.

³ Note: FY21 GAAP Operating income of \$2,354M. For more information and a reconciliation of non-GAAP financial measures, refer to the Company's Current Report on Form 8-K furnished under item 2.02 on November 4, 2021.

⁴ See page 14 for Capex, M&A, Dividends and Share Repurchase data for trailing 5 fiscal years.



#1 Distributor
of specialty pharmaceuticals



3MM+
products shipped daily



#1 Distributor
of animal health products



70,000+
daily deliveries to healthcare facilities

Management team

As of January 1, 2022



Steven H. Collis

Chairman, President and Chief Executive Officer



Silvana Battaglia

Executive Vice President and Chief Human Resources Officer



Elizabeth Campbell

Executive Vice President and Chief Legal Officer



Gina K. Clark

Executive Vice President and Chief Communications and Administration Officer



James F. Cleary

Executive Vice President and Chief Financial Officer



Leslie E. Donato

Executive Vice President and Chief Strategy Officer



Robert P. Mauch

Executive Vice President and Group President

Corporate officers

Steven H. Collis

Chairman, President and Chief Executive Officer

Silvana Battaglia

EVP and Chief Human Resources Officer

Elizabeth Campbell

EVP and Chief Legal Officer

Gina K. Clark

EVP and Chief Communications & Administration Officer

James F. Cleary

EVP and Chief Financial Officer

Leslie E. Donato

EVP and Chief Strategy Officer

Kathy H. Gaddes

EVP and Chief Compliance Officer

Lazarus Krikorian

SVP and Chief Accounting Officer

Robert P. Mauch

EVP and Group President

Kourosh Q. Pirouz

Vice President, Associate General Counsel & Secretary

J.F. Quinn

SVP and Corporate Treasurer

Board of Directors



Steven H. Collis^{5*}

Chairman of the Board,
President and Chief Executive
Officer of AmerisourceBergen
Corporation



Jane E. Henney, M.D.^{5**}

Retired Professor, Internal Medicine
and Public Health Service, College
of Medicine at the University of
Cincinnati and Home Secretary for
the National Academy of Medicine



Ornella Barra^{3, 6}

Chief Operating Officer,
International for Walgreens
Boots Alliance, Inc.



D. Mark Durcan^{1, 3*, 5, 7}

Retired Chief Executive Officer
of Micron Technology, Inc.



Richard W. Gochbauer^{2, 6}

Retired President & Chief Executive Officer
of United Stationers (now Essendant)



Lon R. Greenberg^{4, 5, 6*, 7}

Retired Chairman of the Board
and Chief Executive Officer of
UGI Corporation



Kathleen W. Hyle^{2*, 3, 5}

Former Senior Vice President of
Constellation Energy and Chief
Operating Officer of Constellation
Energy Resources



Michael J. Long^{4, 5, 7*}

Chairman, President and
Chief Executive Officer of
Arrow Electronics, Inc.



Henry W. McGee^{1, 4*, 5}

Senior Lecturer, Harvard
Business School and Retired
President of HBO Home
Entertainment



Dennis M. Nally^{1*, 2, 5, 8}

Retired Chairman of
PricewaterhouseCoopers

Committees of the Board

As of January 1, 2022

- 1 Audit Committee
- 2 Compensation and Succession Planning Committee
- 3 Finance Committee
- 4 Governance, Sustainability and Corporate Responsibility Committee
- 5 Executive Committee
- 6 Compliance and Risk Committee
- 7 Merger Integration Committee
- 8 Special Litigation Committee

* Denotes Committee Chair

** Dr. Jane Henney, as Lead Independent Director, serves as an ex-officio member of each of the Committees.

GAAP/Non-GAAP financial measures

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in addition to, and not in lieu of, financial measures presented in accordance with GAAP. These supplemental measures may vary from, and may not be comparable to, similarly titled measures by other companies.

Adjusted diluted earnings per share excludes the per share impact of adjustments including gains from antitrust litigation settlements; LIFO credit; acquisition-related intangibles amortization; employee severance, litigation, and other; impairment of a non-customer note receivable; gain on remeasurement of an equity investment; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable effective tax rate for those items. In addition, the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted diluted earnings per share. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.

For additional information on our non-GAAP financial measures, please refer to the Company's Current Report on Form 8-K furnished under Item 2.02 on November 4, 2021.

Appendix A: GAAP to Non-GAAP Reconciliations

FY 2021

| (In thousands except per share data) | Operating Income | Diluted EPS ¹ |
|--|--------------------|--------------------------|
| GAAP | \$2,354,197 | \$7.39 |
| Gains from antitrust litigation settlements | (168,794) | (0.58) |
| LIFO credit | (203,028) | (0.70) |
| Acquisition related intangibles amortization | 176,221 | 0.58 |
| Employee severance, litigation, and other ² | 471,911 | 1.84 |
| Impairment of non-customer note receivable | – | 0.07 |
| Gain on remeasurement of equity investment | – | (0.31) |
| Goodwill impairment | 6,373 | 0.03 |
| Impairment of assets | 11,324 | 0.05 |
| Certain discrete tax benefits ³ | – | (0.10) |
| Tax reform ⁴ | – | 0.98 |
| Adjusted non-GAAP⁵ | \$2,648,204 | \$9.26 |

Capital deployment

Fiscal years ended September 30,

| (In thousands) | 2021 | 2020 | 2019 | 2018 | 2017 |
|-------------------|-------------|-----------|-----------|-----------|-----------|
| Capex | \$438,217 | \$369,677 | \$310,222 | \$336,411 | \$466,397 |
| M&A ⁶ | \$5,725,660 | \$56,080 | \$63,951 | \$785,299 | \$72,995 |
| Dividends | \$366,648 | \$343,578 | \$338,974 | \$333,041 | \$320,270 |
| Share Repurchases | \$82,150 | \$420,449 | \$674,031 | \$639,235 | \$329,929 |

¹ Based on 208,456,000 diluted shares outstanding.

² Includes a \$147.7 million legal expense accrual related to opioid litigation settlements.

³ Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business.

⁴ Represents expenses related to U.K. and Swiss tax reform.

⁵ The sum of the components does not equal the total due to rounding.

⁶ Includes \$6.5 billion acquisition of Alliance Healthcare in fiscal 2021.

Corporate information

Cautionary note regarding forward-looking statements

Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company's operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its shareholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

Shareholder services

Our transfer agent, Computershare, can help you with a variety of shareholder services, including:

- Change of address
- Lost stock certificates
- Stock transfer
- Account consolidation

Computershare can be reached at:

Telephone: 866.233.1957 or TDD 800.231.5469

Outside U.S.: 201.680.6578 or TDD 201.680.6610

Internet: www.computershare.com

Mail: AmerisourceBergen Corporation
c/o Computershare
P.O. Box 43078 Providence, RI 02940-3078

Email: Support.ServiceCenter@cpushareownerservices.com

Additional information

Financial documents, such as our Annual Report on Form 10-K, and quarterly reports on Form 10-Q, and other reports and filings, such as the Company's Code of Ethics and Business Conduct, may be obtained from the Company website at investor.amerisourcebergen.com, or by calling the Company's Investor Relations Department at 610.727.7000.

Investor Relations

Shareholders, security analysts, portfolio managers and other investors desiring further information about the Company should contact:

Bennett S. Murphy, SVP, Investor Relations
Phone: 610.727.3693

Email: bmurphy@amerisourcebergen.com

Annual meeting of shareholders

March 10, 2022 at 3:30p.m. Eastern Time
www.virtualshareholdermeeting.com/ABC2022

Independent registered public accounting firm

Ernst & Young LLP, Philadelphia, Pennsylvania

Stock listing

AmerisourceBergen Corporation is listed on The New York Stock Exchange under the symbol ABC.

AmerisourceBergen

We are united in our responsibility
to create healthier futures.